Search

This study describes the prevalence of erectile dysfunction (ED) among 57 men using illicit opioids who presented to a primary care program for buprenorphine therapy. Participants’ mean age was 40 years and 34% reported ED. Low total testosterone was detected in 17% of those reporting ED , but total testosterone was not significantly associated with ED. Examining multiple comorbidities and laboratory parameters, only older age was significantly associated with erectile dysfunction (r=.27, p

Little is known about the use of preventive health services by HIV-seronegative IDUs. This study examines screening and preventive health services use by two populations of HIV-seronegative IDUs recruited from a needle exchange program and methadone program. We found high rates of HIV and tuberculin skin testing in the past year as well as tetanus vaccination among both groups of IDUs. Hepatitis B and C testing was significantly higher in the methadone group than the needle exchange group. Syphilis testing and pneumovax administration was disappointingly low in both groups. Given the burden of disease among IDUs, our findings suggest the need for a distinct set of testing and vaccination guidelines for the HIV-seronegative IDU population.

Surveys of physicians' attitudes regarding the therapeutic value of marijuana are rare. Drawing on a national sample of family physicians, general internists, obstetrician-gynecologists, psychiatrists, and addiction specialists, 960 (adjusted response rate 66%) offered opinions about the legal prescription of marijuana as medical therapy. Thirty-six percent believed prescribed marijuana should be legal and 26% were neutral to the proposition. Non-moralistic attitudes toward substance use were significantly associated with support for physician prescription, as was internal medicine and obstetrics-gynecology specialization. Physicians are, in general, less supportive than the general American public regarding the use of medical marijuana.

Sleep disturbance is common among patients in recovery from alcoholism and can precipitate relapse. Though sleep complaints are commonly managed with medication, little is known about their management among recovering alcoholic patients. We performed a postal survey of a self-weighted, random systematic sample of 503 members of the American Society of Addiction Medicine (ASAM) to examine addiction medicine physicians' medical management of sleep disturbance among patients in early recovery from alcoholism. After 3 mailings, 311 (62%) responded. Of responents, 64% have offered pharmacological treatment to an insomniac, alcoholic patient in the first 3 months after detoxification, but only 22% offered medication to more than half of such patients. Trazodone was the preferred therapy, chosen first by 38% of respondents, followed by other sedating antidepressants (12%), and antihistamines (12%). The mean duration of therapy for trazodone and other sedating antidepressants exceeded one month. Experts in addiction medicine appear reluctant to prescribe medication to sleep-disturbed patients in early recovery from alcoholism. When they do prescribe, trazodone, other sedating antidepressants and antihistamines are favored, despite limited evidence for or against this indication. Although the treatment of disordered sleep among alcoholic patients in early recovery may have merit to prevent relapse, controlled studies of these sleep agents are needed.

Hazardous drinking is common among active injection drug users (IDUs). This report examines: (1) the perceived alcohol and drug treatment needs of a cohort of IDUs, and (2) whether perceived needs predict treatment entry. One hundred and eighty-seven AUDIT-positive (> or = 8), active IDUs were recruited between 2/98-10/99 for the Brief Alcohol Intervention for Needle Exchangers (BRAINE) trial. At entry, about 18% of participants perceived no need for substance abuse treatment, 52% for drug treatment alone, 26% for drug and alcohol treatment, and only 3% a need for alcohol treatment only. Very high levels of drinking and adverse drinking consequences were observed among those perceiving no need for treatment of alcohol problems. Perceived need for alcohol treatment was positively associated with measures of adverse drinking consequences and DSM-IV diagnosis for alcohol dependence. Persons who at baseline perceived the need for alcohol treatment were more likely to enter alcohol treatment at 6-month follow-up than those without a perceived need (20% vs. 5%; p = .006). We conclude that IDUs with co-occurring alcohol-use disorders perceive alcohol treatment needs as less immediate than drug treatment. Because perceived need predicts treatment entry, changing alcohol treatment perceptions in IDUs promises the potential of significant long-term public health benefits.